Trial Profile
A Retrospective study to evaluate the treatment patterns in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate + prednisone or enzalutamide
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jun 2017
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Enzalutamide (Primary) ; Prednisone (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 21 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology